A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
← catalyst calendarNCT07534592 · readout in 8 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
48actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-16 | actual | When the study began enrolling |
| Primary completion | 2026-08-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: Elecoglipron
- Drug: Atorvastatin
- Drug: Rosuvastatin
Primary outcomes
what the primary-completion date above is the date OFArea under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatin
measured Group 1: Day 1 to Day 71
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of atorvastatin
measured Group 1: Day 1 to Day 71
Maximum observed drug concentration (Cmax) of atorvastatin
measured Group 1: Day 1 to Day 71
AUCinf of rosuvastatin
measured Group 2: Day 1 to Day 76
AUClast of rosuvastatin
measured Group 2: Day 1 to Day 76
Cmax of rosuvastatin
measured Group 2: Day 1 to Day 76
Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUCinf (R AUCinf) of atorvastatin
measured Group 1: Day 1 to Day 71
Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUClast (R AUClast) of atorvastatin
measured Group 1: Day 1 to Day 71
Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on Cmax (R Cmax) of atorvastatin
measured Group 1: Day 1 to Day 71
Terminal elimination half-life (t1/2λz) of atorvastatin
measured Group 1: Day 1 to Day 71
Terminal rate constant (λz) of atorvastatin
measured Group 1: Day 1 to Day 71
Time to reach maximum observed concentration (tmax) of atorvastatin
measured Group 1: Day 1 to Day 71
Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUCinf (R AUCinf) of rosuvastatin
measured Group 2: Day 1 to Day 76
Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUClast (R AUClast) of rosuvastatin
measured Group 2: Day 1 to Day 76
Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on Cmax (R Cmax) of rosuvastatin
measured Group 2: Day 1 to Day 76
t1/2λz of rosuvastatin
measured Group 2: Day 1 to Day 76
λz of rosuvastatin
measured Group 2: Day 1 to Day 76
tmax of rosuvastatin
measured Group 2: Day 1 to Day 76
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed